Overview

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Status:
Withdrawn

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.

Phase:

Phase 2

Details

Lead Sponsor:

Stem Cell Therapeutics Corp.

Treatments:

Chorionic Gonadotropin
Epoetin Alfa